Skip to main content

Table 3 Subgroup analyses. Criteria refer to preceding year

From: Consistent use of lipid lowering therapy in HIV infection is associated with low mortality

  1. Top row of each cell shows hazard ratio (95% confidence interval), bottom row p-value followed by [deaths/patient years]. Cells with significant beneficial associations are framed (no multiplicity correction). TDF Use: in patients enrolled ≥ 2001. Low ASCVD risk: no known ASCVD, 10-year PCE risk score < 10%, and native LDL cholesterol < 4.1 mmol/L. High ASCVD risk: either known ASCVD, 10-year PCE risk score >= 10%, or native LDL cholesterol >= 4.1 mmol/L